Cantargia AB’s CAN04 product candidate shows good safety after repeated doses in new toxicity study

Lund March 9, 2016 - Cantargia AB (“Cantargia”) has received data from the
second toxicity study of the company’s CAN04 product candidate. This second
study was conducted using a higher dose level and repeated doses.  In accordance
with the first study, no signs of toxicity were observed.
The new toxicity study investigated repeated treatment with the product
candidate CAN04 at doses up to 10 mg/kg. Following the finalization of the study
the data has been analysed and the results show that the treatment did not give
rise to any negative effects. These results further support that CAN04 will have
a good safety profile in patients and strengthen the positive impression
obtained from single-dose treatment at a dose level of 5 mg/kg in the first
toxicity study that was communicated in November 2015.

“The outcome of the toxicity study is very encouraging, and the results support
our positioning of CAN04 as a safe and effective cancer treatment. We are
continuing our efforts towards the clinical study phase”, CEO Göran Forsberg
says.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com